apomorphine

Summary

Summary: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.

Top Publications

  1. ncbi Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study
    Estelle Dellapina
    INSERM, Imagerie cérébrale et handicaps neurologiques, Toulouse, France
    Mov Disord 26:153-7. 2011
  2. ncbi Subcutaneously administered apomorphine: pharmacokinetics and metabolism
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Neurology 62:S8-11. 2004
  3. pmc Dopamine transporter genotype dependent effects of apomorphine on cold pain tolerance in healthy volunteers
    Roi Treister
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    PLoS ONE 8:e63808. 2013
  4. ncbi Dopaminergic modulation of visual-spatial working memory in Parkinson's disease
    Alberto Costa
    IRCCS, Fondazione Santa Lucia, Universita di Roma Tor Vergata, Italia
    Dement Geriatr Cogn Disord 15:55-66. 2003
  5. ncbi Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease
    R Levy
    Department of Physiology, Faculty of Medicine, University of Toronto, Ontario M5S 1A8, Canada
    J Neurophysiol 86:249-60. 2001
  6. ncbi Involvement of dopamine D2 receptors in apomorphine-induced facilitation of forebrain serotonin output
    A Mendlin
    Program in Neuroscience, Princeton University, NJ 08544 1010, USA
    Eur J Pharmacol 351:291-8. 1998
  7. ncbi Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management
    Angelo Antonini
    Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Via Bignami 1, Milan, Italy
    Expert Rev Neurother 9:859-67. 2009
  8. ncbi Effects of apomorphine on rat behavior in the elevated plus-maze
    Andrea Milena Becerra Garcia
    Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto USP, Av Bandeirantes 3900, 14049 901 Ribeirão Preto SP, Brasil
    Physiol Behav 85:440-7. 2005
  9. ncbi Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study
    A Balcioglu
    Neuroregeneration Laboratories, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Neuroscience 119:1045-53. 2003
  10. ncbi The dopamine agonist apomorphine enhances conditioned pain modulation in healthy humans
    Roi Treister
    Faculty of Social Welfare and Health Sciences, University of Haifa, Israel
    Neurosci Lett 548:115-9. 2013

Research Grants

  1. ULTRASTRUCTURE OF MESOLIMBIC TRANSMITTER INTERACTIONS
    Virginia M Pickel; Fiscal Year: 2012
  2. A Novel Monkey Model for Parkinson's Drug Discovery
    Howard J Federoff; Fiscal Year: 2010
  3. AUTORECEPTOR REGULATION OF DOPAMINE RELEASE
    Greg Gerhardt; Fiscal Year: 1991
  4. Dopamine D2/D3 Receptor Agonists for PET Imaging
    JOGESH MUKHERJEE; Fiscal Year: 2010
  5. MECHANISMS OF CANNABINOIDS ANTIEMETIC ACTIONS
    NISSAR DARMANI; Fiscal Year: 2001
  6. PHARMACOLOGY OF FETAL STRIATAL TISSUE TRANSPLANTS
    Andrew Norman; Fiscal Year: 1992
  7. CHOLINERGIC MECHANISMS IN AGING AND AD
    LINCOLN POTTER; Fiscal Year: 2002
  8. Basal ganglia discharge patterns in parkinsonism
    Thomas Wichmann; Fiscal Year: 2005
  9. BLADDER HYPERACTIVITY AFTER OBSTRUCTION RELIEF
    William Steers; Fiscal Year: 1999
  10. KAINIC ACID AND STRIATAL DOPAMINE TURNOVER
    Robert Schwarcz; Fiscal Year: 1980

Detail Information

Publications310 found, 100 shown here

  1. ncbi Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study
    Estelle Dellapina
    INSERM, Imagerie cérébrale et handicaps neurologiques, Toulouse, France
    Mov Disord 26:153-7. 2011
    ..In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD...
  2. ncbi Subcutaneously administered apomorphine: pharmacokinetics and metabolism
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Neurology 62:S8-11. 2004
    b>Apomorphine is a non-narcotic morphine derivative that acts as a potent dopaminergic agonist...
  3. pmc Dopamine transporter genotype dependent effects of apomorphine on cold pain tolerance in healthy volunteers
    Roi Treister
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    PLoS ONE 8:e63808. 2013
    The aims of this study were to assess the effects of the dopamine agonist apomorphine on experimental pain models in healthy subjects and to explore the possible association between these effects and a common polymorphism within the ..
  4. ncbi Dopaminergic modulation of visual-spatial working memory in Parkinson's disease
    Alberto Costa
    IRCCS, Fondazione Santa Lucia, Universita di Roma Tor Vergata, Italia
    Dement Geriatr Cogn Disord 15:55-66. 2003
    ..and visual-object WM tasks and to investigate the effect of administering the dopaminergic agonist apomorphine (experiment 1) or the dopamine precursor L-dopa (experiment 2) on the performance of tests assessing these ..
  5. ncbi Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease
    R Levy
    Department of Physiology, Faculty of Medicine, University of Toronto, Ontario M5S 1A8, Canada
    J Neurophysiol 86:249-60. 2001
    This study examines the effect of apomorphine (APO), a nonselective D(1)- and D(2)-dopamine receptor agonist, on the firing activity of neurons in the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi) in ..
  6. ncbi Involvement of dopamine D2 receptors in apomorphine-induced facilitation of forebrain serotonin output
    A Mendlin
    Program in Neuroscience, Princeton University, NJ 08544 1010, USA
    Eur J Pharmacol 351:291-8. 1998
    The effect of systemic administration of the nonselective dopamine receptor agonist apomorphine on efflux of serotonin (5-hydroxytryptamine, 5-HT) in striatum and hippocampus of freely moving rats was examined using in vivo microdialysis...
  7. ncbi Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management
    Angelo Antonini
    Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Via Bignami 1, Milan, Italy
    Expert Rev Neurother 9:859-67. 2009
    The continuous infusion of levodopa or apomorphine represents a good therapeutic option for advanced Parkinson's disease as this approach provides constant dopaminergic stimulations and is a good alternative to deep brain stimulation...
  8. ncbi Effects of apomorphine on rat behavior in the elevated plus-maze
    Andrea Milena Becerra Garcia
    Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto USP, Av Bandeirantes 3900, 14049 901 Ribeirão Preto SP, Brasil
    Physiol Behav 85:440-7. 2005
    ..The present study examined the effects of the dopaminergic agonist apomorphine, the D(2) dopaminergic antagonist sulpiride and the combined treatment sulpiride plus apomorphine on ..
  9. ncbi Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study
    A Balcioglu
    Neuroregeneration Laboratories, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Neuroscience 119:1045-53. 2003
    ..microdialysis and high-pressure liquid chromatography under basal conditions and after systemic injections of apomorphine or amphetamine...
  10. ncbi The dopamine agonist apomorphine enhances conditioned pain modulation in healthy humans
    Roi Treister
    Faculty of Social Welfare and Health Sciences, University of Haifa, Israel
    Neurosci Lett 548:115-9. 2013
    ..The current study was aimed to test the effects of apomorphine, a non-specific dopamine agonist, on the magnitude of CPM in healthy subjects...
  11. ncbi Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results
    F Stocchi
    Department of Neurosciences, University of Rome La Sapienza, Italy
    Neurol Sci 22:93-4. 2001
    ..Continuous dopaminergic stimulation can be achieved more easily by infusing dopamine agonists subcutaneously. Apomorphine is a potent water-soluble dopamine receptor agonist that has been shown to successfully control motor ..
  12. pmc Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging
    Chih Jen Wen
    Molecular Imaging Center, Chang Gung Memorial Hospital, Gueishan, Taoyuan, Taiwan
    Int J Nanomedicine 7:1599-611. 2012
    Quantum dots (QDs) and apomorphine were incorporated into liposomes to eliminate uptake by the liver and enhance brain targeting...
  13. ncbi Effects of microinjections of apomorphine and haloperidol into the inferior colliculus on the latent inhibition of the conditioned emotional response
    Liana L Melo
    Laboratorio de Neuropsicofarmacologia, Universidade São Francisco, Braganca Paulista, SP, Brazil
    Exp Neurol 216:16-21. 2009
    ..PE and NPE rats received IC microinjections of physiological saline, the dopaminergic agonist apomorphine (9.0 microg/0.5 microL/side), or the dopaminergic antagonist haloperidol (0.5 microg/0...
  14. ncbi Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients
    Sören Peters
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Neuroreport 14:809-12. 2003
    Our group investigated modulatory effects of apomorphine on cerebral activation patterns during finger tapping movements in seven Parkinson's disease (PD) patients off medication...
  15. pmc Apomorphine reduces subthalamic neuronal entropy in parkinsonian patients
    M Lafreniere-Roula
    Department of Physiology, University of Toronto, Toronto, ON, M5S 1A8, Canada
    Exp Neurol 225:455-8. 2010
    ..of 8 neurons was recorded prior to, during, and following systemic administration of the dopamine agonist apomorphine at clinically effective doses...
  16. pmc Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus
    D De Gaspari
    Centro Parkinson, Istituti Clinici di Pefezionamento, 20126 Milan, Italy
    J Neurol Neurosurg Psychiatry 77:450-3. 2006
    ..The clinical condition of advanced Parkinson's disease (PD) patients is often complicated by motor fluctuations and dyskinesias which are difficult to control with available oral medications...
  17. ncbi Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations
    Ming Jun Tsai
    Food and Drug Administration, Department of Health, Executive Yuan, Taipei, Taiwan
    J Pharm Sci 100:547-57. 2011
    b>Apomorphine, a dopamine receptor agonist for treating Parkinson's disease, has very poor oral bioavailability (<2%) due to the first-pass effect...
  18. ncbi Practical considerations in the use of apomorphine injectable
    Annette Bowron
    Jubilee Day Hospital, North Tyneside General Hospital, Tyne and Wear, United Kingdom
    Neurology 62:S32-6. 2004
    This manuscript provides a practical summary of guidelines for institution of apomorphine subcutaneous injectable therapy, including patient education, pre-treatment issues, dosage titration and side-effect care...
  19. ncbi Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease
    Montse Alegret
    Parkinson s Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Mov Disord 19:1463-9. 2004
    Bilateral subthalamic deep brain stimulation (STN-DBS) and continuous subcutaneous infusion of apomorphine (APM-csi) can provide a comparable improvement on motor function in patients with advanced Parkinson's disease (PD), but the ..
  20. pmc Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic alpha7 receptors
    Katsuya Suemaru
    Division of Pharmacy, Ehime University Hospital, Shitsukawa, Shigenobu cho, Onsen gun, Ehime 791 0295, Japan
    Br J Pharmacol 142:843-50. 2004
    ..effects of nicotine on the disruption of prepulse inhibition (PPI) of the acoustic startle response induced by apomorphine or phencyclidine in rats. Over the dose range tested, nicotine (0.05-1 mg kg(-1), s.c.) did not disrupt PPI...
  21. ncbi Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway
    Hirokazu Hara
    Department of Clinical Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan
    J Neurosci Res 84:860-6. 2006
    ..b>Apomorphine (Apo), a dopamine D(1)/D(2) receptor agonist, is used for clinical therapy of Parkinson's disease...
  22. ncbi Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan
    S H Fox
    Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
    Mov Disord 16:642-50. 2001
    ..We hypothesise that, because dopamine receptor agonists, such as apomorphine, cannot be metabolised to produce noradrenaline, activation of adrenoceptors may not be involved in dyskinesia ..
  23. ncbi Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate
    Silvia Mandel
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology and Rappaport Family Research Institute, Technion Faculty of Medicine, Haifa, 31096, Israel
    J Mol Neurosci 24:401-16. 2004
    ..Radical scavengers such as R-apomorphine and green tea catechin polyphenol (-)-epigallocatechin-3-gallate, as well as the recently developed brain-..
  24. ncbi Apomorphine-induced prepulse inhibition disruption is associated with a paradoxical enhancement of prepulse stimulus reactivity
    Benjamin K Yee
    Laboratory of Behavioural Neurobiology, Swiss Federal Institute of Technology, Zurich, Schwerzenbach, Switzerland
    Neuropsychopharmacology 29:240-8. 2004
    ..Not only did apomorphine (2.0 mg/kg, intraperitoneal (i.p.)) attenuate PPI but it also enhanced reactivity to the prepulse stimulus...
  25. ncbi Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats
    Charles K Meshul
    Research Services, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Exp Neurol 175:257-74. 2002
    ..In lesioned animals, the effect of nicotine on apomorphine-induced contralateral rotations was also assessed...
  26. ncbi Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway'
    A Stefani
    Clinica Neurologica, Univ di Tor Vergata, P le Umanesimo 10, 00144 Rome, Italy
    Clin Neurophysiol 113:91-100. 2002
    ..We have challenged this view, based on the so-called 'indirect pathway', by recording apomorphine effects from both structures of parkinsonian patients, at rest and during passive movements.
  27. ncbi Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia
    Alon Nevet
    Dept of Physiology, The Hebrew University, Hadassah Medical School, P O Box 12272, Jerusalem, 91120 Israel
    J Neurophysiol 92:1973-81. 2004
    ..occur in the activity of the substantia nigra pars reticulata (SNr) of non-parkinsonian (normal) monkeys with apomorphine (APO)-induced orofacial dyskinesia...
  28. ncbi Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice
    Ruxandra Iancu
    Neuronal Survival Unit, Wallenberg Neuroscience Centre, Department of Experimental Medical Sciences, Lunds University, BMC A10, 22184 Lund, Sweden
    Behav Brain Res 162:1-10. 2005
    ..Mice underwent various drug-induced (amphetamine- and apomorphine-induced rotation) and spontaneous motor tests (cylinder, rotarod, elevated body swing, and stride length test)...
  29. ncbi Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges
    Regina Katzenschlager
    Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom
    Mov Disord 20:151-7. 2005
    Continuous subcutaneous (SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug-induced dyskinesias in Parkinson's disease (PD)...
  30. ncbi A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease
    Hilary L Tyne
    The University of Liverpool, UK
    J Neurol 251:1370-4. 2004
    b>Apomorphine is a potent dopamine agonist useful in the treatment of Parkinson's disease patients with disabling motor fluctuations and 'off' periods, not responding to oral medication...
  31. pmc Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks
    Debora L Nickla
    The New England College of Optometry, Dept of Biosciences, 424 Beacon St, Boston, MA 02115, USA
    Exp Eye Res 91:715-20. 2010
    ..Eyes were injected daily at noon, for 4 days, and the lenses immediately replaced. Agonists used were apomorphine (non-specific; n = 17), quinpirole (D2; n = 10), SKF-38393 (D1; n = 9), and saline controls (n = 22)...
  32. ncbi Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients
    Alice J Manson
    The Reta Lila Weston Institute for Neurological Studies, The Middlesex Hospital, London, United Kingdom
    Mov Disord 17:1235-41. 2002
    Continuous subcutaneous infusion of apomorphine is now increasingly recognized as an effective treatment for refractory off periods and peak-dose dyskinesias in Parkinson's disease...
  33. ncbi Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation
    Eri Himeno
    Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Ann Neurol 69:248-56. 2011
    Intracellular amyloid β-protein (Aβ) contributes to neurodegeneration in Alzheimer disease (AD). Apomorphine (APO) is a dopamine receptor agonist for Parkinson disease and also protects against oxidative stress...
  34. pmc Contribution of dopamine receptors to periaqueductal gray-mediated antinociception
    Paul J Meyer
    Department of Psychology, Washington State University Vancouver, Vancouver, WA 98686, USA
    Psychopharmacology (Berl) 204:531-40. 2009
    ..Morphine relieves pain, in part, by acting on neurons within the periaqueductal gray (PAG). Given that the PAG contains a subpopulation of dopamine neurons, dopamine may contribute to the antinociceptive effects mediated by the PAG...
  35. ncbi Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease
    Dirk Deleu
    Department of Neurology Medicine, Hamad Medical Corporation, Doha, State of Qatar
    Drugs Aging 21:687-709. 2004
    b>Apomorphine, a short-acting dopamine D1 and D2 receptor agonist, was the first dopamine receptor agonist used to treat Parkinson's disease...
  36. ncbi Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers
    R Luthringer
    Service du Docteur Jean Paul Macher, centre hospitalier spécialisé, FORENAP Institute for Research in Neurosciences and Psychiatry, Rouffach, France
    Neuropsychobiology 39:49-56. 1999
    b>Apomorphine, a dopamine receptor agonist (given in a dose of 0.75 mg s.c.), was administered to 8 healthy volunteers; electroencephalograph (EEG) and event-related potential (ERP) mapping were performed before dosing and 0.5, 1.5 and 2...
  37. ncbi The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinsonian patients
    Martin Bares
    1st Department of Neurology, Masaryk University, St Anne Hospital, Pekarska 53, 656 91, Brno, Czech Republic
    Parkinsonism Relat Disord 9:139-44. 2003
    ..EOG) recordings in 21 L-DOPA-naive patients suffering from Parkinson's disease (PD) were made before and after apomorphine subcutaneous administration (ASA). The effect of apomorphine on smooth pursuit eye movements (SPEM) was studied...
  38. ncbi Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice
    Rebecca J Ralph-Williams
    Alcohol and Drug Abuse Research Center, Harvard Medical School and McLean Hospital, Belmont, Massachusetts 02478, USA
    J Neurosci 22:9604-11. 2002
    ..Neither the mixed D1/D2 agonist apomorphine (5 mg/kg) nor the more selective D1-like agonist SKF82958 (0...
  39. pmc 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine
    Ellen S Mitchell
    University of Washington, Box 359911, Harborview Medical Center, 325 9th Ave, Seattle, WA 98104, USA
    Pharmacol Biochem Behav 88:291-8. 2008
    ..4368554, a 5-HT6 selective antagonist at a dose of 10 mg/kg, could reverse the loss of prepulse inhibition from apomorphine or scopolamine...
  40. ncbi Effects of acute and chronic apomorphine on sex behavior and copulation-induced neural activation in the male rat
    Jocelien D A Olivier
    Department of Anatomy, UMC St Radboud, University of Nijmegen, The Netherlands
    Eur J Pharmacol 576:61-76. 2007
    b>Apomorphine is a non-selective dopaminergic receptor agonist. Because of its pro-erectile effects, apomorphine is clinically used for treatment of erectile dysfunction...
  41. ncbi Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study
    Pedro J Garcia Ruiz
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Mov Disord 23:1130-6. 2008
    Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations...
  42. ncbi Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
    E Grunblatt
    Eve Topf National Parkinson s Foundation Center for Neurodegenerative Diseases, Technion, Israel
    J Neurochem 77:146-56. 2001
    In order to establish whether the antioxidant and iron-chelating activities of R-apomorphine (R-APO), a D(1)-D(2) receptor agonist, may contribute to its neuroprotective property, its S-isomer, which is not a dopamine agonist, was ..
  43. ncbi Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine
    Kizhakke M Sindhu
    Division of Clinical and Experimental Neuroscience, Indian Institute of Chemical Biology, 4, Raja S C Mullick Road, Calcutta 700 032, India
    Pharmacol Biochem Behav 84:321-9. 2006
    ..b>Apomorphine administration caused contralateral circling behavior in MFB-lesioned animals, but ipsilateral rotations in ..
  44. ncbi Chicks from a high and low feather pecking line of laying hens differ in apomorphine sensitivity
    Yvonne M van Hierden
    Animal Sciences Group of Wageningen UR, Division of Animal Resources Development, Research Group Animal Welfare, P O Box 65, NL 8200, AB Lelystad, The Netherlands
    Physiol Behav 84:471-7. 2005
    Proactive rodents show a larger behavioral response to apomorphine (APO) than reactive copers, suggesting a more sensitive DA system in proactive individuals...
  45. pmc Effect of apomorphine on cognitive performance and sensorimotor gating in humans
    Arnt F A Schellekens
    Department of Psychiatry, Radboud Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
    Psychopharmacology (Berl) 207:559-69. 2010
    ..The objective of the current study was to assess dopamine receptor functioning at the forebrain level...
  46. ncbi Sublingual apomorphine as a neuroendocrine probe
    Ludmila Brunerova
    Mediscan, Euromedic, Prague, Czech Republic
    Psychiatry Res 198:297-9. 2012
    Subcutaneous apomorphine, a dopaminergic agonist, is used as a neuroendocrine probe for assessing central dopaminergic activity. The aim of our study was to test sublingual apomorphine for the same purpose...
  47. ncbi Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug
    Shu Hui Hsu
    Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
    Nanotechnology 21:405101. 2010
    ..An anti-Parkinson's drug, apomorphine, was used as the model drug...
  48. ncbi Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation
    A E Elia
    Istituto Neurologico Carlo Besta, Milan, Italy
    Eur J Neurol 19:76-83. 2012
    ..deep brain stimulation (STN DBS) and continuous dopaminergic infusions (jejunal levodopa or subcutaneous apomorphine) are indicated in complicated Parkinson's disease (PD), although it remains unsettled how they compare to each ..
  49. ncbi Apomorphine effects on episodic memory in young healthy volunteers
    Alonso Montoya
    Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Verdun, Quebec, Canada
    Neuropsychologia 46:292-300. 2008
    ..Frontal lobe DA function may be involved. We were interested in assessing whether apomorphine (Apo), a drug used extensively in clinical research as a probe of DA function, has an effect on episodic memory ..
  50. ncbi Differences in the behavioral profile of circling under amphetamine and apomorphine in rats with unilateral lesions of the substantia nigra
    M Ziegler
    McMaster University, Hamilton, Ontario, Canada
    Behav Neurosci 102:276-88, 327. 1988
    ..into the substantia nigra, amphetamine (2 mg/kg) induces circling towards the side of the lesion and apomorphine (0.25 mg/kg) induces circling in the opposite direction...
  51. ncbi Reversal of apomorphine locomotor sensitization by a single post-conditioning trial treatment with a low autoreceptor dose of apomorphine: a memory re-consolidation approach
    Marinete Pinheiro Carrera
    Behavioral Pharmacology Group, Laboratory of Animal Morphology and Pathology, State University of North Fluminense Darcy Ribeiro, Avenida Alberto Lamego, 2000, Campos dos Goytacazes, 28013 600, RJ, Brazil
    Pharmacol Biochem Behav 99:29-34. 2011
    ..protocol to induce a context specific sensitization to the locomotor stimulant effect of a high dose of apomorphine (2.0mg/kg)...
  52. ncbi Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I: behavioral effects and role of nucleus accumbens
    Rani Sarkis
    Department of Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
    Exp Neurol 228:19-29. 2011
    ..administration of dizocilpine (MK-801), a N-methyl-d-Aspartate (NMDA) noncompetitive receptor antagonist, or apomorphine (APO), a dopamine (DA) D1 and D2 receptor agonist, on neuropathic manifestations in the chronic constriction ..
  53. ncbi Effects of ketamine and apomorphine on inferior colliculus and caudal pontine reticular nucleus evoked potentials during prepulse inhibition of the startle reflex in rats
    Guy Sandner
    I N S E R M U405, Faculte de Medecine, Université Louis Pasteur 11, rue Humann, 67085 Strasbourg Cedex, France
    Behav Brain Res 128:161-8. 2002
    ..PnC), were obtained in freely moving rats during standard startle and PPI tests, under ketamine (5 mg/kg) or apomorphine (0.5 mg/kg)...
  54. ncbi Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease
    Antoniya Todorova
    National Parkinson Foundation Centre of Excellence, Department of Neurology, King s College Hospital, and King s Health Partners, London, UK Electronic address
    Parkinsonism Relat Disord 19:1073-8. 2013
    ..continuous drug delivery have been reported to have a beneficial effect on NMS in PD and while the efficacy of apomorphine on motor function in PD has been confirmed in a number of studies, in addition to its possible anti-dyskinetic ..
  55. ncbi The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controls
    Arnt F A Schellekens
    Department of Psychiatry, University Medical Centre St Radboud, Nijmegen, The Netherlands
    Eur Neuropsychopharmacol 19:68-73. 2009
    ..Little is known on functional changes in the fronto-striatal-thalamic dopaminergic neurocircuitry in these patients. The objective of this study was to assess sensitivity of prefrontal dopamine receptors in alcohol dependent patients...
  56. ncbi Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease
    C Neef
    Medisch Spectrum Twente, Department of Clinical Pharmacy, Enschede, The Netherlands
    Clin Pharmacokinet 37:257-71. 1999
    In the treatment of patients with Parkinson's disease, apomorphine has an established place as a back-up therapy if other antiparkinsonian drugs, such as levodopa and oral dopamine agonists, have not controlled the existing response ..
  57. ncbi Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report
    M P Austin
    Mood Disorders Unit, Prince of Wales Hospital and School of Psychiatry, University of New South Wales, Sydney, 2031, Australia
    Psychiatry Res 97:207-15. 2000
    ..A double-blind, placebo-controlled cross-over design was used to test the effect of apomorphine on motor and cognitive function in seven melancholic subjects (as defined by the CORE instrument) and five ..
  58. ncbi Mismatch negativity is not correlated with neuroendocrine indicators of catecholaminergic activity in healthy subjects
    M Hansenne
    Department of Cognitive Sciences, University of Liege, Belgium
    Hum Psychopharmacol 18:201-5. 2003
    ..Noradrenergic and dopaminergic activities were assessed with the apomorphine and clonidine challenge tests...
  59. ncbi Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures
    Xiaoying Luo
    Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China
    J Neurochem 108:952-61. 2009
    b>Apomorphine (APO), a potent D1/D2 dopamine receptor agonist, is used as an anti-parkinsonian drug...
  60. ncbi The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine
    Janet Hoenicka
    Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    Biol Psychiatry 67:3-11. 2010
    ..The ANKK1 protein nonetheless had yet to be identified. This study examined the ANKK1 expression pattern as a first step to uncover the biological bases of TaqIA-associated phenotypes...
  61. ncbi Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips
    R d'Emmanuele di Villa Bianca
    Dipartimento di Farmacologia Sperimentale, Universita di Napoli Federico II, Naples, Italy
    Int J Impot Res 17:127-33. 2005
    b>Apomorphine is used in the erectile dysfunction therapy and its action has been ascribed to the stimulation of central dopamine receptor...
  62. ncbi Nucleus accumbens dopamine and discriminated approach learning: interactive effects of 6-hydroxydopamine lesions and systemic apomorphine administration
    Jeffrey W Dalley
    Department of Experimental Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK
    Psychopharmacology (Berl) 161:425-33. 2002
    ..Although dopaminergic mechanisms have been implicated in incentive motivational processes, their role in appetitive conditioning remains poorly understood...
  63. ncbi Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease
    A E Di Rosa
    Department of Neuroscience, University of Messina, Via Consolare Valeria, Messina, Italy
    Neurol Sci 24:174-5. 2003
    ..PD) develop cognitive and psychiatric complications more frequently during prolonged therapy with continuous apomorphine infusion compared with standard oral treatment...
  64. ncbi Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose
    Rajesh Pahwa
    University of Kansas Medical Center, 3599 Rainbow Blvd, Kansas City, KS 66160, USA
    J Neurol Sci 258:137-43. 2007
    To further explore the efficacy and safety of subcutaneous apomorphine (APO) in treating off episodes in APO-naïve patients with advanced Parkinson's disease (PD).
  65. ncbi Apomorphine in the treatment of Parkinson's disease
    Rukmini Menon
    Duke University Medical Center, Durham, NC 27705, USA
    Expert Opin Pharmacother 8:1941-50. 2007
    ..b>Apomorphine is a dopaminergic agent that has been known to the medical community for more than a century, but has only ..
  66. ncbi Microinfusion into the rat brain of antibodies against Semliki Forest Virus produces changes in behavioral response to apomorphine
    Paul M Knopf
    Department of Molecular Microbiology and Immunology, Brown University Medical School, Division of Biology and Medicine, Brown University, Providence, RI 02912, USA
    J Neuroimmunol 184:149-55. 2007
    ..rats was determined using a bioassay, measuring rotational locomotion following systemic injection of apomorphine. Anti-SFV IgG-infused rats demonstrated a significantly increased (p<0...
  67. ncbi Nitric oxide modulates apomorphine-induced recognition memory deficits in rats
    Ioannis Gourgiotis
    Department of Pharmacology, School of Medicine, University of Thessaly, Larissa, Greece
    Pharmacol Biochem Behav 102:507-14. 2012
    ..NOS inhibitors to reverse recognition memory impairments produced by the DA D(1)/D(2) mixed receptor agonist apomorphine in rats. For these studies, the novel object recognition test (NORT) was used as the memory test...
  68. ncbi Apomorphine injections: predictors of initial common adverse events and long term tolerability
    William G Ondo
    Department of Neurology, Baylor College of Medicine, 6550 Fannin, Ste 1801, Houston, TX 77030, USA
    Parkinsonism Relat Disord 18:619-22. 2012
    b>Apomorphine injections effectively abort "off" episodes in Parkinson's disease (PD). However, their use is limited by actual and perceived adverse events (AE). To our knowledge, no study has evaluated for predictors of these problems.
  69. pmc Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice
    K Yano
    Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
    Br J Pharmacol 156:173-80. 2009
    ..esterase (AChE) inhibitor and allosteric potentiator of nicotinic ACh receptors (nAChRs), improves apomorphine-induced deficits in prepulse inhibition (PPI), sensory information-processing deficits, via a nAChR-independent ..
  70. ncbi Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition
    R de la Fuente-Fernandez
    Neurodegenerative Disorders Center, University of British Columbia, Vancouver, British Columbia, Canada
    J Cereb Blood Flow Metab 21:1151-9. 2001
    ..to estimate changes in the synaptic level of dopamine ([DA]) induced by direct dopamine agonists (for example, apomorphine) in patients with Parkinson disease...
  71. ncbi Effects of microinjections of apomorphine and haloperidol into the inferior colliculus on prepulse inhibition of the acoustic startle reflex in rat
    Susan Satake
    Laboratório de Psicologia Experimental, Departamento de Biociencias, Universidade Federal de Sao Paulo UNIFESP, Av D Ana Costa, 95, Santos SP 11060 001, Brazil
    Neurosci Lett 509:60-3. 2012
    ..Bilateral microinjections of apomorphine (9.0 μg/0...
  72. pmc Dendritic distributions of dopamine D1 receptors in the rat nucleus accumbens are synergistically affected by startle-evoking auditory stimulation and apomorphine
    Y Hara
    Division of Neurobiology, Department of Neurology and Neuroscience, Weill Medical College of Cornell University 411 East 69th Street KB 410, New York, NY 10021, USA
    Neuroscience 146:1593-605. 2007
    ..stimulation (AS) is a measure of sensorimotor gating that is disrupted by the dopamine D1/D2 receptor agonist, apomorphine. The apomorphine effect on prepulse inhibition is ascribed in part to altered synaptic transmission in the ..
  73. ncbi The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice
    Carolina A Meller
    Graduate Program in Cellular and Molecular Biology, Center for Biotechnology, Federal University of Rio Grande do Sul, 91501 970 Porto Alegre, RS, Brazil
    Peptides 25:585-8. 2004
    ..Stereotyped behaviors induced by the dopamine receptor agonist apomorphine or the N-methyl-D-aspartate glutamate receptor antagonist dizocilpine (MK-801) in rodents have been proposed as ..
  74. ncbi Activation of glutathione peroxidase and inhibition of p53-related apoptosis by apomorphine
    Linqing Ma
    Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    J Alzheimers Dis 27:225-37. 2011
    b>Apomorphine hydrochloride (APO) is known to be a dopamine receptor agonist, and has recently been found to be a novel drug for Alzheimer's disease (AD)...
  75. ncbi A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20126, Milan, Italy
    J Neurol 258:579-85. 2011
    ..effect of deep brain stimulation (DBS) of the subthalamic nucleus (STN) and continuous subcutaneous infusion of apomorphine (CSAI) in patients with advanced Parkinson disease (PD) are lacking...
  76. ncbi The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine
    E Garrido
    Laboratory of Neurosciences, Instituto de Investigacion, Hospital Universitario 12 de Octubre, Avda de Cordoba s n, 28041 Madrid, Spain
    Neurotox Res 20:32-9. 2011
    ..differences in both the nucleus and the cytoplasm at basal level and when stimulated with the dopamine agonist apomorphine. Specifically, the ANKK1-kinase(Thr239) variant showed the highest level of basal protein expression, while ..
  77. ncbi CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats
    F Weiss
    Research Institute of Scripps Clinic, Department of Molecular and Experimental Medicine, La Jolla, CA 92037
    Psychopharmacology (Berl) 99:409-15. 1989
    ..Subcutaneous (SC) injections of apomorphine (APO; 0...
  78. ncbi Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression
    Heather McPherson
    Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, New Zealand
    J Affect Disord 76:121-5. 2003
    ..This was investigated by measuring growth hormone (GH) or prolactin (PRL) response to apomorphine (APO), a dopamine receptor agonist, in patients with bipolar depression, unipolar depression and control ..
  79. ncbi Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease
    L Brusa
    IRCCS Fondazione S Lucia, Via Ardeatina 306, I 00179 Rome, Italy
    Neurol Sci 23:S61-2. 2002
    ..A second DSC-MRI examination performed after subcutaneous apomorphine administration did not show any significant asymmetry in PD patients...
  80. ncbi Perinatal AZT exposure alters the acoustic and tactile startle response to 8-OH-DPAT and apomorphine in adult rats
    Susan M Melnick
    Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Neurotoxicol Teratol 27:599-608. 2005
    ..25 or 0.5 mg/kg 8-OH-DPAT, a 5-HT(1A) agonist, or 0.75 or 2.0 mg/kg apomorphine (APO, a dopaminergic agonist) IP. Both DPAT and APO increased startle magnitude as expected...
  81. ncbi Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice
    Kenta Umeda
    Department of Neuropharmacology Faculty of Pharmaceutical Sciences, Fukuoka University, 8 19 1 Nanakuma, Jonan ku, Fukuoka 814 0180, Japan
    Eur J Pharmacol 553:157-62. 2006
    ..of mood stabilizers on the disruption of prepulse inhibition of the acoustic startle response induced by either apomorphine or dizocilpine in mice. Valproate (30-300 mg/kg, i.p.), carbamazepine (3-30 mg/kg, i.p...
  82. ncbi Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin
    Orly Weinreb
    Eve Topf, Haifa, Israel
    Ann N Y Acad Sci 993:351-61; discussion 387-93. 2003
    ..Dopamine (DA), R-apomorphine (R-APO), green tea polyphenol (-)-epigallocatechine-3-gallate (EGCG), and melatonin are neuroprotective and ..
  83. ncbi Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study
    Francesco Montorsi
    Department of Urology, University Vita e Salute San Raffaele, Via Olgettina 60, 20132, Milan, Italy
    Eur Urol 43:405-11. 2003
    To evaluate the in vivo effect of apomorphine sublingual versus placebo on cortical and subcortical brain activation during video sexual stimulation.
  84. ncbi Adolescent chronic apomorphine treatment impairs latent inhibition and reduces prefrontal cortex mGluR5 receptor expression in adult rats
    Feng Shao
    Department of Psychology, Peking University, Beijing, 100871, China
    Eur J Pharmacol 649:202-5. 2010
    ..In the current study, adolescent Wistar rats were subjected to chronic dopamine agonist apomorphine treatment (1 mg/kg for 14 days)...
  85. ncbi In vitro S100B secretion is reduced by apomorphine: effects of antipsychotics and antioxidants
    Patricia Nardin
    Departamento de Bioquimica, Instituto de Ciencias Basicas da Saude, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
    Prog Neuropsychopharmacol Biol Psychiatry 35:1291-6. 2011
    ..rat brain preparations (fresh hippocampal slices, C6 glioma cells and primary astrocyte cultures) exposed to apomorphine and antipsychotics (haloperidol and risperidone), aiming to evaluate, ex vivo and in vitro, whether dopamine ..
  86. ncbi The effect of apomorphine on blink kinematics in subhuman primates with and without facial nerve palsy
    Robert S Baker
    Department of Ophthalmology, University of Kentucky Medical Center, Lexington, Kentucky 40536, USA
    Invest Ophthalmol Vis Sci 43:2933-8. 2002
    The purpose of this study was to document the effect of acutely delivered apomorphine, a dopamine receptor agonist with both D1 and D2 properties, on blink rate and the amplitude-velocity characteristics of eyelid kinematics in a group ..
  87. ncbi Intermittency in mastication and apomorphine-induced gnawing
    G E Gerstner
    Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor 48109 1078, USA
    Physiol Behav 65:569-74. 1998
    ..The current study evaluates the structure of intermittency associated with mastication and apomorphine-induced gnawing in the guinea pig. Thirteen free-roaming animals were videotaped while masticating or gnawing...
  88. ncbi MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
    Jessica M Castellano
    Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    Peptides 28:2009-15. 2007
    ..trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing ..
  89. ncbi Differential mutagenic, antimutagenic and cytotoxic responses induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in bacteria and yeast
    Jaqueline N Picada
    Centro de Biotecnologia e Departamento de Biofísica, Universidade Federal do Rio Grande do Sul, UFRGS, Av Bento Goncalves 9500, Prédio 43421, Campus do Vale, Caixa Postal 15005, CEP 91501 970, Porto Alegre, RS, Brazil
    Mutat Res 539:29-41. 2003
    b>Apomorphine (APO) is considered to be a classical mixed type dopamine D(1) and D(2) receptor agonist. It has been used in the therapy of Parkinson's disease and, more recently, for the treatment of erectile dysfunction...
  90. ncbi Effect of apomorphine on striatal synaptotagmin 7 mRNA levels in reserpinized rats
    Robert Pal
    Brain Research Laboratory, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Zaloska 4, 1000 Ljubljana, Slovenia
    Neurosci Lett 424:194-8. 2007
    ..We analyzed the effects of apomorphine, a D1 and D2 receptor agonist on Syt 7 mRNA expression in caudate putamen, nucleus accumbens, cingulate cortex, ..
  91. ncbi Apomorphine-susceptible and apomorphine-unsusceptible Wistar rats differ in their recovery from stress-induced ulcers
    S B Degen
    Department of Psychoneuropharmacology, University of Nijmegen, P O Box 9101, NL 6500 HB Nijmegen, The Netherlands
    Life Sci 72:1117-24. 2003
    ..of restraint-in-water-stress on gastric ulcerations in two fundamentally different types of animals: the apomorphine-susceptible (APO-SUS) and apomorphine-unsusceptible (APO-UNSUS) rats...
  92. ncbi Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study
    M Pierantozzi
    Clinica Neurologica, , Tor Vergata, Rome, Italy
    Exp Brain Res 141:52-62. 2001
    ..In all PD patients the same TMS protocols were performed before and after 3 h of apomorphine infusion...
  93. ncbi Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors
    Andrea Gogos
    Behavioral Neuroscience Laboratory, Mental Health Research Institute, 155 Oak St, Parkville Melbourne, Victoria 3052, Australia
    J Pharmacol Exp Ther 333:218-27. 2010
    ..of estrogen treatment to reverse PPI disruption induced by 8-OH-DPAT or the dopamine D(1)/D(2) receptor agonist apomorphine. Part 2 of this study compared these effects to the ability of various antagonists in reversing the action of 8-..
  94. ncbi Dopamine characteristics in rat genotypes with distinct susceptibility to epileptic activity: apomorphine-induced stereotyped gnawing and novelty/amphetamine-induced locomotor stimulation
    N M de Bruin
    NICI Department of Psychoneuropharmacology, University of Nijmegen, Nijmegen, The Netherlands
    Behav Pharmacol 12:517-25. 2001
    ..order in four rat genotypes during baseline and following injection with the dopamine antagonist haloperidol: apomorphine-susceptible (APO-SUS) > WAG/Rij > apomorphine-unsusceptible (APO-UNSUS) and ACI rats...
  95. ncbi Biphasic effect of apomorphine on rat nociception and effect of dopamine D2 receptor antagonists
    Teresa Pelissier
    Programa de Biología Molecular y Clínica, Facultad de Medicina, Universidad de Chile, Chile
    Eur J Pharmacol 546:40-7. 2006
    ..We studied the effects of the D(1)/D(2) receptor agonist apomorphine, as well as the modulatory effects of (S)-(-)-sulpiride (selective D(2) receptor antagonist) and domperidone (..
  96. ncbi Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations
    Justin C Touchon
    Research Services, Neurocytology Laboratory, VA Medical Center, Portland, Oregon 97239, USA
    Synapse 51:287-98. 2004
    ..labeling within nerve terminals making an asymmetrical synaptic contact, and an increase in the number of apomorphine-induced contralateral rotations. [Meshul et al...
  97. ncbi Bell's palsy-induced blepharospasm relieved by passive eyelid closure and responsive to apomorphine
    Luigi Cattaneo
    Dipartimento di Neuroscienze, Sezione di Neurologia, Universita degli Studi di Parma, Via Gramsci 14, 43100 Parma, Italy
    Clin Neurophysiol 116:2348-53. 2005
    ..The involuntary spasm was relieved by passive lowering of the upper eyelid on the paretic side...
  98. pmc Increased burst firing in substantia nigra pars reticulata neurons and enhanced response to selective D2 agonist in hemiparkinsonian rats after repeated administration of apomorphine
    J I Lee
    Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Korean Med Sci 16:636-42. 2001
    ..changes in 6-hydroxydopamine (6-OHDA)-lesioned hemiparkinsonian rats after repeated administrations of apomorphine. Administration of apomorphine (0.32 mg/kg, intraperitoneal, i.p...
  99. ncbi The pharmacological properties and therapeutic use of apomorphine
    Samo Ribaric
    Institute of Pathophysiology, Medical Faculty, University of Ljubljana, Zaloska 4, SI 1000 Ljubljana, Slovenia
    Molecules 17:5289-309. 2012
    b>Apomorphine (APO) is an aporphine derivative used in human and veterinary medicine...
  100. ncbi Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease
    Yong Wang
    Department of Physiology and Pathophysiology, School of Medicine, Xi an Jiaotong University, Xi an 710061, China
    Brain Res 1310:189-99. 2010
    ..In the present study, apomorphine-induced circling behavior and extracellular firing activity of substantia nigra pars reticulata (SNr) neurons ..
  101. ncbi Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Parkinsonism Relat Disord 15:S97-100. 2009
    ..Continuous duodenal L-dopa or subcutaneous apomorphine infusions are helpful strategies because they can control motor complications by providing continuous ..

Research Grants63

  1. ULTRASTRUCTURE OF MESOLIMBIC TRANSMITTER INTERACTIONS
    Virginia M Pickel; Fiscal Year: 2012
    ..In rodent models, acute systemic administration of either D1/D2 (apomorphine) or D2/D3 (quinpirole) receptor agonists results in a sensorimotor gating deficit that can be measured by the ..
  2. A Novel Monkey Model for Parkinson's Drug Discovery
    Howard J Federoff; Fiscal Year: 2010
    ..by 18fluoro-methyl tyrosine PET imaging and a Clinical Rating Scale (CRS) off and on levodopa and apomorphine. At euthanasia brains will be harvested for histological analysis of neuropathology, neurochemistry and gene ..
  3. AUTORECEPTOR REGULATION OF DOPAMINE RELEASE
    Greg Gerhardt; Fiscal Year: 1991
    ..be administered chronically include, the direct acting dopamine agonists, pergolide (D2), SKF 38393 (D1) and apomorphine (D1,D2); the nonselective dopamine antagonist haloperidol, the D2 selective antagonist sulpride, the D1 ..
  4. Dopamine D2/D3 Receptor Agonists for PET Imaging
    JOGESH MUKHERJEE; Fiscal Year: 2010
    ..have now accomplished imaging only the HA-state of dopamine D2/D3 receptors using aminotetralin-based and apomorphine-based PET radiotracers...
  5. MECHANISMS OF CANNABINOIDS ANTIEMETIC ACTIONS
    NISSAR DARMANI; Fiscal Year: 2001
    ..Pretreatment with either delta9-THC or D2-receptor antagonists prevent the emesis produced by apomorphine (a dopamine D2 agonist) in the least shrew)...
  6. PHARMACOLOGY OF FETAL STRIATAL TISSUE TRANSPLANTS
    Andrew Norman; Fiscal Year: 1992
    ..will be investigated in rats with unilateral striatal KA lesions by assessing rotation behavior in response to apomorphine and D-amphetamine...
  7. CHOLINERGIC MECHANISMS IN AGING AND AD
    LINCOLN POTTER; Fiscal Year: 2002
    ..to affect spontaneous left forearm use by itself or in right hemi-PD, but is expected to alter responses to apomorphine (dopamine agonist), pilocarpine and xanomeline (muscarinic agonists)...
  8. Basal ganglia discharge patterns in parkinsonism
    Thomas Wichmann; Fiscal Year: 2005
    ..in oscillatory activity in basal ganglia and cortex induced by microinjections of the dopamine receptor agonist apomorphine at striatal and extrastriatal basal ganglia sites in parkinsonian animals. The experiments under S.A...
  9. BLADDER HYPERACTIVITY AFTER OBSTRUCTION RELIEF
    William Steers; Fiscal Year: 1999
    ..by: 1) evaluating the in vivo responses of smooth muscle to carbachol, and bladder neurons to capsaicin or apomorphine. 2) determining whether changes in smooth muscle content or contractility neuronal size, GAP-43 expression in ..
  10. KAINIC ACID AND STRIATAL DOPAMINE TURNOVER
    Robert Schwarcz; Fiscal Year: 1980
    ..tried to regulate or modify this increase by intrastriatal or intranigral injections of two dopaminergic drugs, apomorphine and haloperidol...
  11. Effects of DA D1 and D2 agonists on reward sensitivity
    Valeri Farmer Dougan; Fiscal Year: 2004
    ..a D3 selective agonist PD 128,907 used to control for D3 receptor effects, and a non-selective DA agonist, apomorphine; 2) how the value of the available operant reward and the value of adjunctive behaviors changes when animals ..
  12. Utility of Muscarinic Agonists in Schizopherenia
    Edward McGuire; Fiscal Year: 2005
    ..of CDD-0304 and analogs to modulate the impairment of pre-pulse inhibition associated with administration of apomorphine, a dopamine agonist. The ability of compounds to enhance cognitive function also will be evaluated...
  13. Continuous Dopaminergic Stimulation: Parkinson's Disease
    Thomas Smith; Fiscal Year: 2005
    ..Formulate sustained release suspensions for the dopaminergic agonist apomorphine. 2. Test the in vitro release-by-time characteristics of these formulations into buffer. 3...
  14. SENSORY GATING AND HABITUATION IN SCHIZOPHRENIA
    David Braff; Fiscal Year: 2002
    ..depletions of nucleus accumbens DA will be tested in the PPI paradigm following systemic treatments with apomorphine, noradrenergic agonists, and/or various dopaminergic antagonists...
  15. Inhaled dopamine agonist for late stage Parkinsonism
    Joshua Rabinowitz; Fiscal Year: 2003
    ..most effective pharmacological treatments for "off' periods are dopamine agonists, with the dopamine agonist apomorphine especially effective...
  16. BEHAVIORAL & BIOCHEMICAL CORRELATES OF DOPAMINE RESPONSE
    Bahr Weiss; Fiscal Year: 1993
    ..that it is possible to reverse this behavioral supersensitivity in mice by the continuous administration of apomorphine or selective dopaminergic agonists...
  17. PERTUSSIS TOXIN AND EFFECTS OF PSYCHOSTIMULANT DRUGS
    NORMAN URETSKY; Fiscal Year: 2000
    ..as targets for PTX in increasing spontaneous locomotor activity and the stimulant effects of amphetamine and apomorphine; 3) To determine whether D1 receptor mediated events are enhanced and are associated with a change in the ..
  18. INSTRUMENTAL LEARNING AND TOLERANCE TO STIMULANTS
    DAVID WOLGIN; Fiscal Year: 2001
    ..4) To determine whether rats can learn to suppress stereotyped movements induced by cocaine cathinone, and apomorphine. 5) To understand the conditions responsible for the dissipation of tolerance in bottle- and (6) cannula-fed ..
  19. FUNCTIONAL PROPERTIES OF VTA NEURONS
    Ann Kosobud; Fiscal Year: 2000
    ..the basic electrophysiological properties of these neurons, and determine their response to two drug probes, apomorphine (which inhibits DA neurons through actions at autoreceptors) and alfentanil (a short-acting ,mu-opiate agonist ..
  20. Testing Dopaminergic Function Using Pharmacologic FMRI
    Kevin Black; Fiscal Year: 2003
    ..functional MRI to measure cerebral blood oxygen-level dependent (COLD) responses to the mixed dopamine agonist apomorphine in normal humans...
  21. BEHAVIORAL REGULATION OF NEUROENDOCRINE CELLS
    EMILIE RISSMAN; Fiscal Year: 2005
    ..behavior and social preferences are deficient in ERaKO males and females, treatment with the dopamine agonist apomorphine can reinstate normal behavior...
  22. Novel Neurotensin Analogs as Antischizoprenics
    THOMAS DIX; Fiscal Year: 2002
    ..active and representative compounds in two key predictive behavioral models of schizophrenia: a) antagonizing apomorphine reversal of prepulse inhibition of acoustic startle, b) blocking the locomotor activity stimulant effect of D-..
  23. CORTICO-STRIATAL SUBSTRATES OF DEFICIENT STARTLE GATING
    Neal R Swerdlow; Fiscal Year: 2010
    ..New information from these studies will be a foundation for innovative models of the pathophysiology of schizophrenia and other inherited neuropsychiatric disorders, and for prospective strategies for novel drug development. ..
  24. Neural basis of heritable DA-mediated gating deficits
    Neal R Swerdlow; Fiscal Year: 2010
    ..PPI is also impaired in rats by DA agonists e.g. apomorphine (APO) and amphetamine (AMPH) - and sensitivity to these effects appears to be genetically determined in rats, ..
  25. NEURAL CIRCUITRY OF SENSORIMOTOR GATING ACROSS SPECIES
    Neal Swerdlow; Fiscal Year: 2006
    ....
  26. Neuroscience at the Boundaries of Neurology and Psychiatry
    Neal Swerdlow; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  27. A Simple Measure for Studying Sensory Gating Deficits
    Neal Swerdlow; Fiscal Year: 2007
    ..abstract_text> ..
  28. INTERACTIONS OF NEUROTRANSMITTERS IN THE BASAL GANGLIA
    SALLY BOYSON; Fiscal Year: 1990
    ..to the behavioral output of the striatum will be assessed by monitoring the sensitivity of treated rats to apomorphine-induced stereotypy (related to DA) and quipazine-induced "wet dog shakes" (related to serotonin)...
  29. ALTERATIONS IN BRAIN DOPAMINE SYSTEMS FOLLOWING TRIETHYL
    Thomas Walsh; Fiscal Year: 1991
    ..pharmacological and behavioral studies demonstrating an augmented behavioral response to both direct (apomorphine and indirect-acting (d-ampehtamine) dopamine agonists concomitant with an enhanced reactivity of dopamine-..
  30. AUTONOMIC TRANSMISSION
    John Long; Fiscal Year: 1980
    ..They are effective orally. However, in experiments involving the CNS, DK-118 is about 1/3 as active as apomorphine on pre- and post-synaptic sites...
  31. GRAFTING GENETICALLY MODIFIED CELLS TO THE BRAIN
    Fred Gage; Fiscal Year: 2000
    ..The catecholamine-producing cells will be tested for their ability to ameliorate the apomorphine-induced rotational behavior in rats with unilateral lesions of the substantia nigra...
  32. Mentored Patient-Oriented Research Careeer Development Award
    Sharin Sakurai; Fiscal Year: 2003
    ..Finally, the dopamine agonist, apomorphine, will be administered to determine whether the deficits in motor performance and in cerebral activation can be ..
  33. A Novel Animal Model of Relevance to Schizophrenia
    David Feifel; Fiscal Year: 2009
    ..The successful development of this animal model could significantly enhance the understanding of the underlying causes of schizophrenia-associated abnormalities and improve drug discovery. ..
  34. Antipsychotic-Like Drug Effects of Neurotensin
    David Feifel; Fiscal Year: 2004
    ....
  35. Effects of Stress on Pathology of Parkinson's Disease
    GERLINDE METZ; Fiscal Year: 2004
    ..These approaches will provide the opportunity to understand factors involved in the pathology of PD and to develop novel therapeutic strategies for neurodegenerative motor disorders. ..
  36. Serotonin Club IUPHAR Satellite Meeting
    Mark Geyer; Fiscal Year: 2006
    ..Hence, helping neuroscientists-in-training attend the meeting will have a positive influence on trainees and a lasting impact on the field. [unreadable] [unreadable] [unreadable]..
  37. DEVELOPMENTAL MODELS OF GATING DEFICITS IN SCHIZOPHRENIA
    Mark A Geyer; Fiscal Year: 2010
    ..Hence, Aim 3 studies will test the hypothesized differential roles of specific CRF receptors in mediating isolation rearing-induced deficits in PPI in mice, using CRF-R1 and CRF-R2 null mutant mice. ..
  38. INTEROCEPTIVE DRUG CUE CONDITIONING OF COCAINE EFFECTS
    Robert Carey; Fiscal Year: 2002
    ..This research is important for the identification of the ways interoceptive drug cues can activate or inactivate cocaine conditioned stimuli. ..
  39. STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    Mark Geyer; Fiscal Year: 2004
    ..This information will have important implications for the further development of therapeutic approaches to the treatment of both schizophrenia and drug abuse. ..
  40. Novel brain stimulation to enhance stroke recovery
    Esteban Fridman; Fiscal Year: 2004
    ..In addition, it will provide some insight into mechanisms underlying such recovery. Since stroke is the leading cause of motor disabilities this work has a clear clinical relevance. ..
  41. Molecular Basis of D1 and D2 Priming
    Alexia Pollack; Fiscal Year: 2003
    ..Elucidation of this mechanism could lead to treatment strategies aimed to prevent these dyskinesias, which would, in turn, lengthen the time that dopamine replacement therapy is effective to treat patients with PD. ..
  42. Probing D2 receptor in vivo
    Dah Ren Hwang; Fiscal Year: 2003
    ..In addition to schizophrenia, this radiotracer will provide a useful tool for characterization of dopamine transmission at the D2 receptor in a variety of other conditions, such as ADHD, Parkinson's disease, and substance abuse. ..
  43. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC WOODWARD HOPF; Fiscal Year: 2010
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  44. Dopamine regulates drug and social reward interactions
    Zuoxin Wang; Fiscal Year: 2009
    ..abstract_text> ..
  45. Central mechanisms of chronic trigeminal pain
    GEOFFREY GERSTNER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  46. Simulated Human Pharmacokinetics in Rat: Methylphenidate
    Ronald Kuczenski; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  47. Lateral Hypothalamus, Dopamine and Ingestive Behavior
    David Wirtshafter; Fiscal Year: 2007
    ..Gaining an understanding of these systems is a prerequisite for the rational development of novel treatments for disturbances of ingestion, such as occur in obesity, bulemia and cahchexia. [unreadable] [unreadable] [unreadable]..
  48. DOPAMINE TRANSPORTER AGENTS AGAINST COCAINE DEPENDENCE
    ALOKE DUTTA; Fiscal Year: 2007
    ..Compounds selected based on their in vitro activity will be tested for effects on locomotor activity and drug discrimination and self-administration studies to assess their potential in replacement therapy. ..
  49. BASAL GANGLIA CIRCUITRY IMMEDIATE EARLY GENE EXPRESSION
    David Wirtshafter; Fiscal Year: 2003
    ..Other studies will examine the effects of lesions within the basal ganglia on the IEG expression induced by systemic administration of dopaminergic drugs. ..
  50. Multiple Factors Affecting Placebo Response in PD
    Christopher Goetz; Fiscal Year: 2004
    ..Defining these determinant influences will help enhance placebo responses in clinical practice and control them in clinical trials. ..
  51. DETERMINANTS OF DRUG CHOICE
    William Woolverton; Fiscal Year: 2004
    ..Further, an understanding of the variables that control the choice to self-administer a drug is crucial to the refinement of drug abuse treatment. ..
  52. Primate Model of the Transition to Cocaine Addiction
    JAMES ROWLETT; Fiscal Year: 2005
    ..The results will provide needed information for developing a nonhuman primate model that can serve as a quantitative platform for future research on neuroadaptations underlying the transition to persistent cocaine self-administration. ..
  53. DOPAMINERGIC MECHANISMS IN STIMULANT SELF-ADMINISTRATION
    William Woolverton; Fiscal Year: 2005
    ..abstract_text> ..
  54. Dopamine D4 Receptor in Sustained Attention
    Kehong Zhang; Fiscal Year: 2003
    ..The findings may also provide a pharmacological basis for innovative treatment for ADHD to replace stimulant therapy. ..
  55. Brain dopamine alterations in human cocaine users
    KARLEY LITTLE; Fiscal Year: 2006
    ..Goal #4 is to confirm these increases and determine if induction of related genes occurs in human cocaine users. Specific Aim # 4 is to test the hypotheses that COX-1, NHE-1 and related mRNA's are increased in dopamine neurons. ..
  56. Na Channels in Afferents after Bladder Obstruction
    William Steers; Fiscal Year: 2006
    ..Insight into these cellular processes could be exploited to develop afferent based treatments for OAB employing pharmacologic, molecular or gene based strategies. ..
  57. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2003
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  58. Translational Genetic Study of Fear and Anxiety
    ABRAHAM PALMER; Fiscal Year: 2007
    ..This training program will prepare the candidate for an academic career focused on the use of endophenotypes, animal models and bioinformatics to elucidate the genetic basis of psychiatric disease. [unreadable] [unreadable]..
  59. New PET Radiotracers-Monoamine Transporters
    Michael Kilbourn; Fiscal Year: 2003
    ....
  60. Opioids and Conditional Amygdala NMDA Receptor Knockout
    Michael Glass; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..